Despite significant advances in the management of advanced or recurrent endometrial cancer (EC)—including the use of molecular classification, immune checkpoint inhibitors, and targeted therapies—delivering timely, guideline-compliant care remains complex. Rapidly evolving clinical evidence, the growing role…
Antibody-drug conjugates (ADCs) are redefining precision oncology by delivering potent therapies directly to tumor cells through highly specific molecular targeting. This innovative approach is rapidly becoming a cornerstone of cancer care, particularly in metastatic non-small cell…
Metastatic non-small cell lung cancer (mNSCLC) remains a leading cause of cancer mortality despite advances with targeted therapy and immune checkpoint inhibitors (ICIs). While PD-1/PD-L1 blockade has improved outcomes, most patients ultimately progress, and durable responses…
Despite advancements in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), resistance and recurrence occur frequently and mutations might develop during treatment. Given the diverse range of treatment side effects,…
Driven by new insights into tumor biology and immune response, the therapeutic landscape for advanced renal cell carcinoma (RCC) continues to rapidly expand. As immunotherapy and VEGF-targeted combinations become central to RCC management, oncology teams must…
Von Hippel-Lindau (VHL) disease is associated with a range of tumor types that require timely recognition and coordinated management. Accurate diagnosis depends on careful evaluation of clinical presentation, imaging findings, and genetic assessment, as these insights…
Von Hippel-Lindau (VHL) disease is a rare, heritable condition in which approximately 80% of affected individuals have an affected parent, underscoring the critical importance of early identification and surveillance. However, its rarity and variable presentation can…
Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder characterized by tumor predisposition and a wide spectrum of neurologic manifestations. Among its most serious complications are plexiform neurofibromas (PNs), which can cause significant morbidity…
Immune checkpoint inhibitors (ICIs) have transformed the landscape of oncology, achieving remarkable outcomes across tumor types. As outcomes improve and focus shifts to patient-centered care, however, the burden of ongoing treatment continues to impact patient quality…
Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face…